JMJose MarÍA Morales

Jose MarÍA Morales

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jose MarÍA Morales has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • El Grupo de Trasplante Renal de la Sociedad Española de Nefrología

    by Julio Pascual, J M Cruzado, Angel Alonso, Fritz Diekman, R Gallego, Alex Gutierrezdalmau, Domingo Hernandez, J M Morales, Emilio Rodrigo, S Zarraga


  • Open Access

    Renal transplantation in patients with hepatitis C virus antibody. A long national experience

    by Jose MarÍA Morales, Roberto MarcÉN, Amado Andres, Beatriz DomÍNguez-Gil, Josep MarÍA Campistol, Roberto Gallego, Alex Gutierrez, Miguel Angel Gentil, Federico Oppenheimer, MarÍA Luz Samaniego, et al.

    Background. Renal transplantation is the best therapy for patients with hepatitis C virus (HCV) infection with end-stage renal disease. Patient and graft survival are lower in the long term compared with HCV-negative patients. The current study evaluated the results of renal transplantation in Spain in a long period (1990–2002), focusing on graft failure. Methods. Data on the Spanish Chronic Allograft Nephropathy Study Group including 4304 renal transplant recipients, 587 of them with HCV antibody, were used to estimate graft and patient survival at 4 years with multivariate Cox models. Results. Among recipients alive with graft function 1 year post-transplant, the 4-year graft survival was 92.8% in the whole group; this was significantly better in HCV-negative vs HCV-positive patients (94.4% vs 89.5%, P < 0.005). Notably, HCV patients showed more acute rejection, a higher degree of proteinuria accompanied by a diminution of renal function, more graft biopsies and lesions of de novo glomerulonephritis and transplant glomerulopathy. Serum creatinine and proteinuria at 1 year, acute rejection, HCV positivity and systolic blood pressure were independent risk factors for graft loss. Patient survival was 96.3% in the whole group, showing a significant difference between HCV-negative vs HCV-positive patients (96.6% vs 94.5%, P < 0.05). Serum creatinine and diastolic blood pressure at 1 year, HCV positivity and recipient age were independent risk factors for patient death. Conclusions. Renal transplantation is an effective therapy for HCV-positive patients with good survival but inferior than results obtained in HCV-negative patients in the short term. Notably, HCV-associated renal damage appears early with proteinuria, elevated serum creatinine showing chronic allograft nephropathy, transplant glomerulopathy and, less frequently, HCV-associated de novo glomerulonephritis. We suggest that HCV infection should be recognized as a true risk factor for graft failure, and preventive measures could include pre-transplant therapy with interferon.


  • Cholesterol Crystal Embolization

    by José M. Morales, Esther Gonzalez


  • Open Access

    Sirolimus Does Not Exhibit Nephrotoxicity Compared to Cyclosporine in Renal Transplant Recipients

    by José M. Morales, Lars Wramner, Henri Kreis, Dominique Durand, Josep M. Campistol, Amado Andres, Joaquin Arenas, Eric Nègre, James T. Burke, Carl G. Groth

    Sirolimus and cyclosporine (CsA) prevent acute rejection in man when used as primary therapies in triple drug regimens. Sirolimus does not act via the calcineurin pathway and therefore is not expected to produce the same renal side-effects. This paper presents the pooled 2-year data analysis of renal function parameters from two open-label, randomized, multicenter studies. Patients (18–68 years) receiving a primary renal allograft were randomized to receive concentration-controlled sirolimus (n = 81) or CsA (n = 80), in combination with azathioprine and steroids (n = 83), or mycophenolate mofetil (MMF) and steroids (n = 78). From week 10 through year 2, calculated glomerular filtration rate (GFR) was significantly higher in sirolimus- than in CsA-treated patients (69.3 vs. 56.8 mL/min, at 2 years, p = 0.004). Serum uric acid was significantly higher in the CsA-treated patients and magnesium was significantly lower; these parameters were more likely to be within normal limits in the sirolimus group. Mean serum potassium and phosphorus were lower in sirolimus-treated patients. In conclusion, sirolimus, when administered as primary therapy in combination with azathioprine or MMF, has a favorable safety profile compared to CsA with regards to renal function.


  • Tacrolimus, mycophenolate mofetil and corticosteroids as primary immunosuppression after renal transplantation at the Hospital 12 De Octubre, Madrid

    by J.M Morales, A Andrés, E Morales, J.C Herrero, A Cubas, M Praga, E Hernández, T Ortuño, B Dominguez-Gil, A Carreño, et al.